Who
John A. Stalfort III
Director
Company insider
Files Form 4 as: Director, Acumen Pharmaceuticals; Director, Taysha Gene Therapies; Director, Verrica Pharmaceuticals; Director, Dova Pharmaceuticals.
In numbers
- Trades disclosed
- 40
- Buys
- 8
- Sells
- 0
- Bought
- $2.3M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 19 Jun 2018
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,250 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —35,500 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —21,335 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,671 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,671 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —21,335 at $0.00 | filing |
| 4 Jun 2025filed 5 Jun 2025 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 4 Jun 2025filed 5 Jun 2025 | ABOS Acumen PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,800 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —113,246 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —56,623 at $0.00 | filing |
| 26 Nov 2024filed 26 Nov 2024 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —50,000 at $0.00 | filing |
| 22 Nov 2024filed 26 Nov 2024 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —561,797 | filing |
| 22 Nov 2024filed 26 Nov 2024 | VRCA Verrica Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —561,797 | filing |
| 22 Nov 2024filed 26 Nov 2024 | VRCA Verrica PharmaceuticalsBiotechnology | SEC FORM 4 Bought | —1,123,595 | filing |
| 10 Jun 2024filed 10 Jun 2024 | ABOS Acumen Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,440 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code A | —49,220 at $0.00 | filing |
| 16 Aug 2023filed 16 Aug 2023 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Bought | $350K388,889 at $0.90 | filing |
News
Head-To-Head Survey: Taysha Gene Therapies (NASDAQ:TSHA) vs. MediWound (NASDAQ:MDWD)TSHA · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name John A. Stalfort III; 1 article from the last 14 days about the 3 companies they traded most, at most three about any one of them.